NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,464.68 -11.24 (-0.06%) CRUDE OIL
78.45 +0.34 (+0.44%) GOLD FUTURES
2,323.60 +15.00 (+0.65%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
51,139.98 +605.31 (+1.20%)
Calliditas Therapeutics AB (publ) (LC8.F)
- Zacks
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- PR Newswire
Calliditas Therapeutics' 2023 Annual Report Published
Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com
- PR Newswire
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.
